SLC22A17 and cardiomyopathy: Most research was done on doxorubicin-induced cardiomyopathy and for seven genetic variants in CELF4, GPR35, HAS3, RARG, SLC22A17, SLC22A7 and SLC28A3, replication studies were performed without consistent results.